Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT02950987

Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
150 (estimated)
Sponsor
Dana-Farber Cancer Institute · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

This study is evaluating Whole Body MRI as a possible screening tool to diagnose cancer for people with LFS and other inherited cancer predisposition syndromes.

Detailed description

Individuals who carry the TP53 mutation have a higher risk of developing different types of cancer over their lifetimes. This gene has been associated with Li Fraumeni syndrome in some families, but not all families that have cancer histories consistent with Li Fraumeni syndrome will have the mutation. Currently, there is no standard method of monitoring LFS carriers, family members, or others individuals with cancer predisposition syndromes to detect cancers in the early stages, when they may be more easily treated. The main aim of the study is to test a relatively new medical technology called Whole Body Magnetic Resonance Imaging (MRI), in patients with these syndromes, to see if cancers can be detected at an early stage which may, in turn, allow for more effective treatment. The investigators have chosen Whole Body MRI scanning because this scan allows doctors to look at the entire body in one examination. By using this technology, participants are not exposed to radiation, which is of particular importance for individuals who have a higher cancer risk due to a diagnosis of LFS.

Conditions

Interventions

TypeNameDescription
DEVICEWhole Body MRI

Timeline

Start date
2012-03-01
Primary completion
2027-12-01
Completion
2027-12-01
First posted
2016-11-01
Last updated
2026-01-07

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02950987. Inclusion in this directory is not an endorsement.